

COVID-19 Pneumonia

**A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia**

**Trial Status**  
Completed

**Trial Runs In**  
9 Countries

**Trial Identifier**  
NCT04320615 2020-001154-22  
WA42380

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

This study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics of tocilizumab (TCZ) compared with a matching placebo in combination with standard of care (SOC) in hospitalized patients with severe COVID-19 pneumonia.

**Hoffmann-La Roche**  
Sponsor

**Phase 3**  
Phase

---

**NCT04320615 2020-001154-22 WA42380**  
Trial Identifiers

---

***Eligibility Criteria:***

**Gender**  
All

**Age**  
≥18 Years

**Healthy Volunteers**  
No

---